Healthcare product and device company Abbott Laboratories (NYSE: ABT) will be announcing earnings results tomorrow before the bell. Here’s what to look for.
Abbott Laboratories met analysts’ revenue expectations last quarter, reporting revenues of $10.97 billion, up 7.2% year on year. It was a decent quarter for the company, with organic revenue and EPS in line with analysts’ estimates.
Is Abbott Laboratories a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Abbott Laboratories’s revenue to grow 4.3% year on year to $10.39 billion, improving from the 2.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.07 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Abbott Laboratories has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Abbott Laboratories’s peers in the healthcare equipment and supplies segment, only Neogen has reported results so far. It missed analysts’ revenue estimates by 1.5%, posting year-on-year sales declines of 3.4%. The stock was down 20% on the results.
Read our full analysis of Neogen’s earnings results here.Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
